Andere Sprachen Alpha Tau Medical Ltd.

Aktien

A3DG50

IL0011839383

DRTS

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:01 06.05.2024			% 5 Tage	% 1. Jan.
2,46 ^USD	-1,20 %		+2,50 %	-18,27 %

07.03.	Alpha Tau Medical Ltd. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI
2023	Alpha Tau Medical Ltd. gibt Zwischenergebnisse der Sicherheits- und Machbarkeitsstudie zur Behandlung von fortgeschrittenem Bauchspeicheldrüsenkrebs mit Alpha DaRT bekannt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow	06.05.
Alpha Tau to Participate in May Investor Conferences	01.05.
Alpha Tau to Present at the Jefferies Radiopharma Innovation Summit	25.03.
Alpha Tau Medical : to Present at the Jefferies Radiopharma Innovation Summit - Form 6-K	25.03.
Alpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update	07.03.
Alpha Tau Medical Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	07.03.
Alpha Tau Medical : Corporate Presentation – March 2024	04.03.
Alpha Tau to Participate in Barclays 26th Annual Global Healthcare Conference	26.02.
Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference	20.12.
Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference	20.12.
Alpha Tau to Participate in Sidoti Small-Cap Conference	29.11.
Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer	28.11.
Alpha Tau Medical Ltd. Announces Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer	28.11.
Alpha Tau, HekaBio Seek Japan's Premarket Approval of Alpha-Radiation Therapy for Head, Neck Cancer	20.11.
Alpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer	20.11.
Alpha Tau Medical Ltd. Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer	20.11.
Alpha Tau Medical Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	16.11.
Alpha Tau Medical Announces Third Quarter 2023 Financial Results and Provides Corporate Update	16.11.
Alpha Tau to Participate in November Investor Conferences	01.11.
Alpha Tau Enters Into Long-Term Lease of Site in New Hampshire for Second U.S. Manufacturing Facility	30.10.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Alpha Tau Medical Ltd.

Aktien

A3DG50

IL0011839383

DRTS

Andere Sprachen

Filter